Gilead buys out cash-hun­gry part­ner Jounce's an­ti­body for $67M

Gilead Sci­ences has bought out Jounce Ther­a­peu­tics’ an­ti-CCR8 an­ti­body for $67 mil­lion, tak­ing over full R&D and com­mer­cial rights to the ex­per­i­men­tal can­cer im­munother­a­py drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER